Modern Flu Vaccine Application Rejected by FDA
Recently, the FDA made the surprising decision to refuse reviewing Moderna’s application for a new flu vaccine. This move has raised concerns about the agency’s stance towards drug companies and the overall vaccine policies of the current administration.
Biologics director Vinay Prasad has been known for subjecting vaccines to stricter scrutiny than his predecessors, which is significant given Health Secretary Robert F. Kennedy Jr.’s history as a vaccine critic. The core issue in Moderna’s rejection revolves around the choice of the existing influenza vaccine that the company should have used as a control during testing the efficacy of its new shot, which leverages the same mRNA technology as its Covid-19 vaccine. For more insights, you can delve into STAT’s in-depth coverage by Matthew Herper and Helen Branswell.
Declining Confidence in Vaccine Safety
According to new polling data from the University of Pennsylvania’s Annenberg Public Policy Center, confidence in the safety of flu, Covid-19, and MMR vaccines seems to be on a downward trend. The survey conducted between Nov. 17 and Dec. 1 revealed a drop in public perception regarding the safety of these vaccines compared to previous years.
In the survey, 83% of adults viewed the MMR vaccine as safe, while the corresponding figures for flu and Covid vaccines were 80% and 65%, respectively. This decline in trust is concerning, especially amid ongoing measles outbreaks and a challenging flu season. The data shows a significant drop in confidence between 2025 and 2022, emphasizing the need for proactive measures to address vaccine safety concerns. – Helen Branswell
Landmark Legal Ruling to Protect Harm Reduction Programs
A groundbreaking legal settlement in Washington state has established a precedent safeguarding harm reduction programs like syringe exchanges under the Americans with Disabilities Act. This law has historically been instrumental in preserving access to addiction treatment, particularly medications.
ACLU attorney Malhar Shah highlighted the importance of ensuring that individuals who use illegal drugs have access to life-saving services such as needle exchange programs. The case sheds light on the intersection of drug use, addiction, and ADA protections. For a comprehensive analysis, refer to STAT’s coverage by Lev Facher.
FDA Initiates Review of BHA Safety
The FDA is set to reassess the safety of a chemical preservative known as butylated hydroxyanisole (BHA), commonly used in various food products. This move comes in response to growing concerns about the preservative’s impact on consumer health, especially in foods like potato chips, cereal, bread, frozen food, and meat products.
As part of its agenda to enhance oversight of chemicals in the food supply, the FDA has requested additional information on BHA to evaluate its safety in current food applications. This development underscores the agency’s commitment to ensuring the safety of food additives. – Source: The AP
Study Reveals Concerning Trends in Baby Food Products
A recent study published in Nutrients highlighted alarming findings regarding baby food products, with 71% of them classified as ultra-processed foods. These ultra-processed products were found to contain significantly higher levels of sugar, sodium, and calories compared to their non-processed counterparts.
The study, which focused on complementary foods for infants, raises questions about the nutritional quality of baby food and its potential impact on taste preferences and dietary habits. The authors suggest that consuming ultra-processed foods during infancy could have long-term implications on health and eating behaviors. For more insights, revisit STAT’s coverage on the rise of ultra-processed baby foods.
Addressing Exclusion of Rare Disease Patients in Clinical Trials
Theron Odlaug, a former health care leader turned rare disease advocate, shared his personal experience with navigating clinical trials for his granddaughter, who has Dravet syndrome. In a poignant essay, Odlaug reflects on the challenges faced by families seeking access to experimental therapies for rare diseases.
He emphasizes the need for incentives to encourage greater inclusivity in clinical trials, especially for patients with rare conditions who often find themselves excluded from research studies. By shedding light on the barriers to participation in clinical trials, Odlaug advocates for a more inclusive approach to drug development. – Source: First Opinion
Recommended Reads
- FTC targets medical nonprofits in trans kids’ health probe – Bloomberg
- The babies kept in a mysterious Los Angeles mansion – New Yorker
- Novartis’ biomedical research head on AI, pruning the pipeline, and a potential blockbuster – STAT
- This complex brain network may explain many of Parkinson’s stranger symptoms – NPR
- We tested the government’s official new A.I. nutrition tool: Grok – STAT
